Segesterone Acetate And Ethinyl Estradiol

Drug Overview

The combination of segesterone acetate and ethinyl estradiol represents a significant advancement in the Gynecology category. This medication belongs to the Drug Class of Combined Contraceptive (Vaginal Ring). Unlike traditional daily pills, this system provides a long-acting, user-controlled method of birth control that offers convenience and high efficacy.

As a potent Hormone Modulator, this vaginal ring provides a steady release of hormones directly through the vaginal wall, allowing for lower systemic peaks compared to some oral options. It is uniquely designed to be used for an entire year (13 cycles), making it a sustainable and cost-effective choice for many women.

• Generic Name: Segesterone acetate and ethinyl estradiol.
• US Brand Names: Annovera.
• Route of Administration: Vaginal (Insertable ring).
• FDA Approval Status: FDA-approved for the prevention of pregnancy in women of reproductive potential.

What Is It and How Does It Work? (Mechanism of Action)

This medication functions as a systemic Hormone Modulator that regulates the delicate signaling between the brain and the ovaries, known as the hypothalamic-pituitary-ovarian (HPO) axis.

At the molecular and hormonal level, the mechanism is dual-action:

• HPO Axis Modulation: Segesterone acetate (a potent progestin) and ethinyl estradiol (estrogen) work together to inhibit the release of Gonadotropin-Releasing Hormone (GnRH) from the hypothalamus. This, in turn, prevents the pituitary gland from secreting Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH).
• Inhibition of Ovulation: By suppressing FSH and LH, the medication prevents the maturation of ovarian follicles and the mid-cycle LH surge. Without the LH surge, ovulation (the release of an egg) does not occur.
• Cervical and Endometrial Changes: The progestin component also thickens the cervical mucus, creating a physical barrier to sperm. Additionally, it alters the uterine lining (endometrium), making it less receptive to implantation.

Because it delivers hormones through the vaginal mucosa, it is a form of Targeted Therapy that achieves consistent therapeutic levels while avoiding the “first-pass metabolism” by the liver that occurs with oral tablets.

FDA-Approved Clinical Indications

The primary role of this combined ring is for long-term reproductive control.

Primary Gynecological Indications

• Pregnancy Prevention: Indicated for use by females of reproductive potential to prevent pregnancy.

Off-Label / Endocrinological Indications

• Cycle Regulation: Often used off-label to manage irregular menstrual cycles or to predict timing of withdrawal bleeding.
• Dysmenorrhea Management: Reduction of painful menstrual cramping by suppressing the natural cycle and thinning the endometrial lining.
• Endometriosis Support: Use as a Hormone Modulator to suppress estrogen-dependent growth of ectopic endometrial tissue, thereby reducing pelvic pain.

Dosage and Administration Protocols

This system is a single ring intended for use over 13 consecutive 28-day cycles (1 year).

Important Considerations:

• BMI Limitations: The efficacy of this specific ring has not been adequately studied in women with a Body Mass Index (BMI) greater than 29 kg/m². Research indicates a potential decrease in efficacy and increased risk of complications in this population.
• Renal/Hepatic Insufficiency: Steroid hormones are metabolized in the liver. This medication is contraindicated in patients with acute hepatitis or severe hepatic impairment.

Clinical Efficacy and Research Results

Clinical trials evaluating the segesterone acetate/ethinyl estradiol ring (2020-2026) have demonstrated high rates of success in preventing pregnancy.

• Pearl Index: In large-scale clinical trials, the Pearl Index (the number of unintended pregnancies per 100 woman-years of use) was calculated at 2.98. This indicates that the ring is over 97% effective with typical use.
• Bleeding Profile: Data show that approximately 92% of women experienced predictable withdrawal bleeding during the 7-day “ring-out” period.
• Vaginal Health: Research indicates that the ring does not significantly alter the vaginal microbiome or pH levels over 13 cycles of use.
• Patient Compliance: Because the user does not need to remember a daily pill, clinical data shows a 10% to 15% increase in “perfect use” adherence compared to oral contraceptives.

Safety Profile and Side Effects

BLACK BOX WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS

Cigarette smoking increases the risk of serious cardiovascular side effects from combined hormonal contraceptive use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. Women who are over 35 years old and smoke should not use combined hormonal contraceptives.

Common Side Effects (>10%)

• Headache or Migraine.
• Nausea and vomiting.
• Vaginal yeast infections (Candidiasis) and increased discharge.
• Breast tenderness or discomfort.
• Painful menses (Dysmenorrhea).

Serious Adverse Events

• VTE/Thrombosis Risk: Increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE).
• Liver Disease: Rare instances of benign or malignant liver tumors.
• Toxic Shock Syndrome (TSS): While extremely rare, users should be aware of the signs of TSS, as the ring is a foreign body in the vagina.

Management Strategies

• If the Ring Falls Out: If the ring is out of the vagina for more than 2 hours (cumulatively) during the 21-day “in” phase, a backup method of contraception (e.g., condoms) must be used for 7 days.
• Vaginal Irritation: If persistent irritation or unusual discharge occurs, a medical evaluation for infection is required.

Research Areas

In the field of reproductive health, current Research Areas are focusing on the development of multi-purpose prevention technologies (MPTs). This includes using the vaginal ring as a platform for Targeted Therapy to deliver both contraceptives and microbicides that protect against HIV and other STIs. Additionally, researchers are investigating the use of the segesterone ring in the context of endometrial regeneration. While the ring itself is not a Biologic, scientists are exploring how its steady-state hormone delivery might stabilize the endometrial stem cell niche in women recovering from uterine synechiae (Asherman’s Syndrome).

Disclaimer: The research described regarding the segesterone acetate ring as a platform for microbicides or its role in stabilizing the endometrial stem cell niche for Asherman’s Syndrome is currently exploratory and largely based on emerging or theoretical findings. These concepts remain under investigation and are not yet validated in large-scale clinical trials or established medical practice. Therefore, they are not applicable to current practical or professional clinical decision-making scenarios.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed:

• Pregnancy Test: Must confirm negative status before initial insertion.
• Blood Pressure: Baseline measurement to screen for hypertension.
• BMI Assessment: Evaluation of weight to ensure the patient is within the studied efficacy range (BMI less than 29).
• Cytology: Routine cervical cancer screening (Pap smear) as per standard guidelines.

Precautions during treatment:

• Symptom Vigilance: Patients must be taught the “ACHES” acronym (Abdominal pain, Chest pain, Headaches, Eye problems, Severe leg pain) to identify potential blood clots.
• Storage: The ring must be kept at room temperature and away from direct sunlight.

Do’s and Don’ts List:

• DO use a backup contraceptive for the first 7 days of use in the very first cycle.
• DO check for the presence of the ring regularly (e.g., after sexual intercourse).
• DON’T use oil-based vaginal products (e.g., certain antifungal creams), as they may degrade the silicone of the ring.
• DON’T leave the ring out for more than 7 days during the withdrawal week, or the HPO axis may restart, increasing pregnancy risk.

Legal Disclaimer

This guide is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment from a qualified healthcare provider. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this document.